MedTrace Logo

Intravitreal Aflibercept for Submacular Hemorrhage

NCT03169660 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-02-21

No results posted yet for this study

Summary

The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD. However, one major limitation of VIEW study was that lack of data regarding eyes with submacular hemorrhage. The purpose of the present study was to evaluate the efficacy of Eylea in submacular hemorrhage secondary to exudative AMD.

Conditions

  • Exudative Age-related Macular Degeneration

Interventions

DRUG

Vascular endothelial growth factor trap-eye

Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Kim's Eye Hospital

    lead OTHER

Principal Investigators

  • Jong Woo Kim, M.D. · Kim's Eye Hospital, Seoul, South Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2019-01-20
Completion
2019-01-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03169660 on ClinicalTrials.gov